Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults.
[6] Eptinezumab was approved for medical use in the United States in February 2020,[9][10] and in the European Union in January 2022.
[7][11] Eptinezumab is a fully human monoclonal antibody, blocking the calcitonin gene-related peptide (CGRP) from binding its receptor.
[10] Trials were conducted at 212 sites in United States, Georgia, Russia, Ukraine and the European Union.
[10] The benefit of eptinezumab in comparison to placebo was assessed based on the change in the number of migraine days per month during the first three-month treatment period.